2 weeks Ago By Defense World Staff
Sei Investments Co. trimmed its position in shares of Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX – Free Report) by 0.
8% during the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm owned 55,727 shares of the company’s stock after selling 429 shares during the period. Sei Investments Co.
owned about 0.06% of Crinetics Pharmaceuticals worth $2,849,000 at the end of the most recent reporting period. Several other hedge funds have also recently added to or reduced their stakes in the company.
Barclays PLC grew its position in shares of Crinetics Pharmaceuticals by 75.5% in the 3rd quarter. Barclays PLC now owns 207,712 shares of the company’s stock valued at $10,614,000 after buying an additional 89,358 shares during the last quarter.
Franklin Resources Inc. grew its holdings in shares of Crinetics Pharmaceuticals by 61.4% during the third quarter.
Franklin Resources Inc. now owns 1,390,110 shares of the company’s stock worth $73,815,000 after purchasing an additional 528,688 shares during the last quarter. Geode Capital Management LLC increased its position in shares of Crinetics Pharmaceuticals by 10.
1% during the third quarter. Geode Capital Management LLC now owns 1,848,133 shares of the company’s stock worth $94,458,000 after purchasing an additional 169,746 shares in the last quarter. SG Americas Securities LLC increased its position in shares of Crinetics Pharmaceuticals by 4,084.
6% during the fourth quarter. SG Americas Securities LLC now owns 542,446 shares of the company’s stock worth $27,735,000 after purchasing an additional 529,483 shares in the last quarter. Finally, JPMorgan Chase & Co.
lifted its holdings in shares of Crinetics Pharmaceuticals by 0.3% in the 3rd quarter. JPMorgan Chase & Co.
now owns 285,956 shares of the company’s stock valued at $14,612,000 after purchasing an additional 894 shares during the last quarter. Institutional investors and hedge funds own 98.51% of the company’s stock.
Crinetics Pharmaceuticals Trading Down 6.9 %NASDAQ CRNX opened at $26.89 on Friday.
Crinetics Pharmaceuticals, Inc. has a 1 year low of $26.48 and a 1 year high of $62.
53. The company has a market cap of $2.50 billion, a PE ratio of -7.
21 and a beta of 0.37. The stock’s 50-day moving average price is $35.
19 and its two-hundred day moving average price is $46.80. Crinetics Pharmaceuticals (NASDAQ:CRNX – Get Free Report) last announced its quarterly earnings data on Thursday, February 27th.
The company reported ($0.88) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.92) by $0.
04. Research analysts forecast that Crinetics Pharmaceuticals, Inc. will post -3.
73 EPS for the current fiscal year. Analysts Set New Price TargetsA number of research analysts have commented on the stock. JMP Securities restated a “market outperform” rating and issued a $87.
00 price objective on shares of Crinetics Pharmaceuticals in a research note on Monday, December 16th. TD Cowen began coverage on Crinetics Pharmaceuticals in a research note on Tuesday, February 11th. They set a “buy” rating for the company.
HC Wainwright reiterated a “buy” rating and issued a $81.00 target price on shares of Crinetics Pharmaceuticals in a research note on Monday, January 13th. Stifel Nicolaus started coverage on Crinetics Pharmaceuticals in a research note on Tuesday, March 25th.
They set a “buy” rating and a $60.00 price target for the company. Finally, Wolfe Research began coverage on shares of Crinetics Pharmaceuticals in a research note on Tuesday, February 4th.
They issued a “peer perform” rating on the stock. One equities research analyst has rated the stock with a hold rating and twelve have issued a buy rating to the company’s stock. According to MarketBeat.
com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $73.00.Read Our Latest Report on Crinetics PharmaceuticalsInsiders Place Their BetsIn other news, insider Dana Pizzuti sold 5,000 shares of the firm’s stock in a transaction on Monday, February 3rd.
The shares were sold at an average price of $39.07, for a total value of $195,350.00.
Following the sale, the insider now owns 31,748 shares in the company, valued at approximately $1,240,394.36. This trade represents a 13.
61 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Also, CEO Richard Scott Struthers sold 17,338 shares of the company’s stock in a transaction dated Wednesday, March 19th.
The shares were sold at an average price of $34.20, for a total transaction of $592,959.60.
Following the transaction, the chief executive officer now directly owns 329,147 shares of the company’s stock, valued at $11,256,827.40. This represents a 5.
00 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 32,015 shares of company stock valued at $1,119,263 over the last three months.
6.00% of the stock is currently owned by insiders. Crinetics Pharmaceuticals Company Profile (Free Report)Crinetics Pharmaceuticals, Inc, a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors.
The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors.Read MoreFive stocks we like better than Crinetics PharmaceuticalsWhy Invest in 5G? How to Invest in 5G Stocks Archer Aviation’s Africa Deal Could Boost ACHR StockWhat is Forex and How Does it Work? Are Short Sellers Wrong About These 3 Semiconductor Stocks?Manufacturing Stocks InvestingBoeing Gets $50B in March Orders—Is BA Stock a Buy Now?Want to see what other hedge funds are holding CRNX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Crinetics Pharmaceuticals, Inc.
(NASDAQ:CRNX – Free Report)..
